About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

LONDON (AFX) - EiRx Therapeutics PLC, the healthcare company specialising in
the control of programmed life and death of cells (apoptosis), said OSI
Pharmaceuticals has opted to license four of its drug targets, thereby
triggering first milestone payment with a potential value of up to 18.8 mln usd.
In a statement, the company said OSI Pharmaceuticals has opted to license
and take forward four of its gene targets into drug discovery for oncology.
A success fee for each target is payable by OSI Pharmaceuticals, as part of
a deal consisting of upfront access and consultancy fees, potential success fees
for each target elected by OSI Pharmaceuticals to license and potential
milestone payments based on successful commercialisation of a novel therapeutic
with respect to each such target.
newsdesk@afxnews.com
ra/ak

so what you reckon, news tomorrow from ERX re Oncology

I'm away this week so will not be posting till next week up in bonny Scotland.

what. so you not going to be around when the news is announced then

Driver have fun in Scotland, and the sp will still probably be .30 when you get back !!! : )

of interest : )

Physiomics PLC
07 November 2006


Physiomics plc ('Physiomics' or the 'Company')


Ordinary Shares of 0.04p


The Company was today informed of the following shareholdings:


EiRx Pharma Limited:
134,834,208 shares representing 36.0 % of the Company's issued share capital


Zyzygy plc:
25,000,000 shares representing 6.7 % of the Company's issued share capital


Billam plc:
41,232,844 shares representing 11.0 % of the Company's issued share capital


Zyzygy plc acquired 25,000,000 shares and Billam plc acquired 33,333,333 shares
in the placing first announced on 1 September 2006.


This information is provided by RNS

Incestuous investments.

and whats wrong with that ;-)

Dont be touchy, did I say there was anything wrong with it?

up and no buys, just sells.. very odd

in case any of you are wondering why ZYZ are buying PYC shares, think about it, our director sits on ZYZ board, to take over PYC we will need a controlling share, ZYZ bought ERX shares in 2005 for .0030 and are now selling ERX at .0030, reason.. M&A taking place.

I also think the reason why this is happening is ERX know how much money is coming from OSI and MGI and its far more than we were estimating.

rerating - M&A def on the cards

last chance... rumour of news tomorrow

???? just looking back to see where you said that before ! : )

Be fair smiler, at least this time the word rumour is included.
LOL

I'd heard there was only a rumour that there may be a rumour of news tomorrow, or Monday...maybe Tuesday or perhaps some other day! ;-)
kim

financials out tomorrow

OK NO FINANCIALS.

Were you the only one who did not know that they are not due yet PH?!!
kim

hehehehe they are due in december.. but noone said anything. ;-)

a little trap

Ewing's Sarcoma - Apoptotic And Anti-angiogenic Therapies Work Better Together Than Alone
Main Category: Cancer / Oncology News
Article Date: 13 Nov 2006 - 0:00am (PST)
| email this article | printer friendly | view or write opinions |



Useful Article?
Digg It

Del.icio.us



Prague, Czech Republic: American researchers have found that giving a combination of imantanib (Glivec [1]) and a drug that induces cell death (apoptosis) was better at inhibiting the growth of Ewing's sarcoma in mice than either therapy on its own.

Imantanib works by preventing the creation of new blood vessels to supply the growing tumour (anti-angiogenesis) and the researchers believe that this is the first report of synergy between apoptosis and anti-angiogenic therapy in pre-clinical work.

Professor Andrea Hayes-Jordan reported to the EORTC-NCI-AACR [2] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Friday 10 November) that treating sarcoma cells with imantanib inhibited a growth factor called PDGFR-beta. This had the effect of increasing the sensitivity of the cells to a drug called tumour necrosis factor-related apoptosis-inducing ligand (TRAIL).

Prof Hayes-Jordan, assistant professor of surgery and pediatrics at the MD Anderson Cancer Center, Houston, USA, said: "When I treated the tumour cells with imantanib, the anti-angiogenic drug, the receptors for TRAIL, the apoptotic drug, increased, thus increasing the efficacy of TRAIL. This was supported by the mouse studies, which showed increased inhibition of pulmonary metastases and primary tumour growth when both were used simultaneously. These findings are important because, if it proves to be effective in humans, it would be well tolerated and have significantly fewer side effects than traditional cytotoxic therapy. Also, at present, we have no effective chemotherapy for pulmonary metastases - the only effective treatment is surgery - so this would give us another option."

Prof Hayes-Jordan hopes to investigate the dual therapy in humans in a clinical trial within 12-18 months.

Abstract no: 474

1. Glivec is known as Gleevac or Gleevec in the USA.
2. EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research].